<DOC>
	<DOCNO>NCT00691548</DOCNO>
	<brief_summary>Non invasive imaging cetuximab uptake PET could help select patient could treat cetuximab , register expensive monoclonal antibody EGFR . Other monoclonal antibody label Zirconium-89 already use success patient . The combination cetuximab label Zirconium-89 promise new probe determine cetuximab uptake , test various pre-clinical animal model Maastricht excellent result . We propose two step study design ( see figure 1 ) . As ultimate goal future determine uptake 89Zr-cetuximab tumour therapy , need investigate toxicity two consecutive low dos 89Zr-cetuximab first place . However , future study patient , also possible single , large dose 89Zr-cetuximab need obtain best image quality , also investigate toxicity single large dose . Step 1 : Determination toxicity two low dos 89Zr-cetuximab In three patient standard load dose 400 mg/m2 cetuximab administer , partly label 89Zr ( 60 MBq , 2.5mg ) day 0 . On day 14 , second injection dose 250 mg/m2 cetuximab , partly label 89Zr ( 60 MBq , 2.5mg ) , give . Step 2 : Determination toxicity one large dose 89Zr-cetuximab A standard load dose 400 mg/m2 cetuximab administer 3 patient , part label 89Zr ( 120MBq , 5mg ) .</brief_summary>
	<brief_title>Non-invasive Imaging Cetuximab-Zr . 89 Uptake Wit PET : Phase I Trial Stage IV Cancer Patients</brief_title>
	<detailed_description>Toxicity score twice week day first injection ( day 0 ) day 14 , accord CTCAE3.0 scoring system . As 14 day , activity Zr89 low ( four half-lives Zr89 4 x 3.2 day = 12.8 day ) , additional toxic effect expect . Blood sample do weekly ( haematology , liver kidney function ) . When 0/3 patient toxicity grade 3 occur step 2 consider safe . If 1/3 patient grade 3 occur , 3 patient included step . If another grade 3 toxicity occur 1/3 patient , study stop . When maximum 1/6 patient experience grade 3 toxicity , step consider safe . When step 2 consider safe , study end . After injection , visualization tumour site analyze perform PET-CT scan day 4 , 5 6 post injection . An additional scan day 3 7 optional . * At day 5 post injection perfusion PET-CT perform .</detailed_description>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion criterion : Stage IV cancer ( primary recurrent ) Normal white blood cell count formula Normal platelet count No anemia require blood transfusion erythropoietin Adequate hepatic function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) institution ; ALT , AST , alkaline phosphatase ≤ 2.5 x ULN institution ) . Calculated Creatinin clearance least 60 ml/min No previous administration cetuximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Stage IV cancer</keyword>
</DOC>